Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 6,313 shares, a decrease of 46.2% from the August 15th total of 11,736 shares. Based on an average trading volume of 2,072 shares, the short-interest ratio is currently 3.0 days.
Oculis Stock Performance
OCSAW stock traded down $0.82 on Tuesday, hitting $3.01. 401 shares of the company were exchanged, compared to its average volume of 5,421. Oculis has a twelve month low of $3.01 and a twelve month high of $22.64. The business’s fifty day moving average is $4.57 and its two-hundred day moving average is $10.17.
Oculis Company Profile
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Further Reading
- Five stocks we like better than Oculis
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
